Cell Cycle Checkpoint Models for Cellular Pharmacology of Paclitaxel and Platinum Drugs
暂无分享,去创建一个
[1] R. Jackson,et al. The problem of the quiescent cancer cell. , 1989, Advances in enzyme regulation.
[2] H. Skipper,et al. The effects of chemotherapy on the kinetics of leukemic cell behavior. , 1965, Cancer research.
[3] A. Photiou,et al. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines , 2005, Journal of Cancer Research and Clinical Oncology.
[4] M. Karlsson,et al. Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. , 2001, The Journal of pharmacology and experimental therapeutics.
[5] G. Samimi,et al. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters , 2006, Cancer Chemotherapy and Pharmacology.
[6] L. Montanaro,et al. Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines , 2002, Molecular pathology : MP.
[7] A Swierniak,et al. Optimal control problems arising in cell‐cycle‐specific cancer chemotherapy , 1996, Cell proliferation.
[8] D. Osella,et al. Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS). , 2004, Journal of inorganic biochemistry.
[9] P. Kiener,et al. Activation of p34cdc2 coincident with taxol-induced apoptosis. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[10] Timothy W. Secomb,et al. Theoretical Analyses and Simulations of Anticancer Drug Delivery , 2004 .
[11] Dominique Barbolosi,et al. Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy-Toxicity Mathematical Model , 2000, Comput. Biomed. Res..
[12] G. Steel,et al. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. , 1979, International journal of radiation oncology, biology, physics.
[13] N. Aronson,et al. Chemotherapy sensitivity and resistance assays: a systematic review. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] H. Eichholtz-Wirth,et al. Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro. , 1980, British Journal of Cancer.
[15] Dennis M. Brown. Drug delivery systems in cancer therapy , 2003 .
[16] K. L. Donaldson,et al. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle , 1994, International journal of cancer.
[17] Evelyn D. Lobo,et al. Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro , 2008, AAPS PharmSci.
[18] S N Gardner,et al. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.
[19] Paolo Magni,et al. Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.
[20] B. Chauffert,et al. Kinetic resistance to anticancer agents , 2004, Cytotechnology.
[21] P Ubezio,et al. Measuring the complexity of cell cycle arrest and killing of drugs: kinetics of phase-specific effects induced by taxol. , 1999, Cytometry.
[22] Shuzhong Zhang,et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.
[23] D. Jonas,et al. Loss of in vitro cytotoxicity of cisplatin after storage as stock solution in cell culture medium at various temperatures , 1997, Cancer.
[24] J. Masters,et al. DNA Repair capacity and cisplatin sensitivity of human testis tumour cells , 1997, International journal of cancer.
[25] R. Riccardi,et al. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. , 1995, European journal of cancer.
[26] P. Vrignaud,et al. Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture. , 1986, Oncology.
[27] R. Margolis,et al. Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells , 1996, The Journal of cell biology.
[28] M. Tilby,et al. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. , 1994, Cancer research.
[29] M. Welters,et al. Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines , 1997, International journal of cancer.
[30] J. Testa,et al. In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo , 2005, British Journal of Cancer.
[31] Y. Sugiyama,et al. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. , 1989, Cancer research.
[32] V. Knick,et al. Evaluation of arylmethylaminopropanediols by a novel in vitro pharmacodynamic assay: correlation with antitumor activity in vivo. , 1990, Cancer research.
[33] H. Minderman,et al. Rational design of irinotecan administration based on preclinical models. , 1998, Oncology.
[34] S. Retsas,et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin , 2000, Anti-cancer drugs.
[35] Lewis B. Sheiner,et al. Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[36] G. Samimi,et al. The cellular pharmacology of oxaliplatin resistance. , 2002, European journal of cancer.
[37] D. Adams. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. , 1989, Cancer research.
[38] Bingya Liu,et al. Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine. , 2004, World journal of gastroenterology.
[39] S. Horwitz,et al. Mechanisms of Taxol-induced cell death are concentration dependent. , 1998, Cancer research.
[40] M. Berger,et al. Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines. , 1999, Neuro-oncology.
[41] F. Szoka,et al. Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes , 2004, Cancer Research.
[42] O. Olopade,et al. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. , 1997, Molecular pharmacology.
[43] E. Pasquier,et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. , 2004, Molecular cancer therapeutics.
[44] W R Greco,et al. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. , 1998, Cancer research.
[45] M. Wientjes,et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. , 1998, Cancer research.
[46] M. Matsuyama,et al. Characteristics of three human gastric cancer cell lines, NU-GC-2, NU-GC-3 and NU-GC-4 , 1988, The Japanese journal of surgery.
[47] M. Shah,et al. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] M E Fisher,et al. A mathematical model of cancer chemotherapy with an optimal selection of parameters. , 1990, Mathematical biosciences.
[49] S. Loewe. The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.
[50] J. Goodisman,et al. Experimental and theoretical studies on the pharmacodynamics of cisplatin in jurkat cells. , 2004, Chemical research in toxicology.
[51] A. Garnier-Suillerot,et al. Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin , 2003, JBIC Journal of Biological Inorganic Chemistry.
[52] William J. Jusko,et al. A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[53] P. Köpf-Maier,et al. Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas , 2004, Cancer Chemotherapy and Pharmacology.
[54] S. Hector,et al. In vitro studies on the mechanisms of oxaliplatin resistance , 2001, Cancer Chemotherapy and Pharmacology.
[55] John Carl Panetta,et al. Optimal Control Applied to Cell-Cycle-Specific Cancer Chemotherapy , 2000, SIAM J. Appl. Math..
[56] D. Kern,et al. In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). , 1988, Cancer research.
[57] J. Au,et al. A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect , 2000, Cancer Chemotherapy and Pharmacology.
[58] Sandia Report,et al. Condence Region Estimation Techniques for Nonlinear Regression: Three Case Studies , 2005 .
[59] M. Somerfield,et al. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Yuichi Sugiyama,et al. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product , 2004, Cancer Chemotherapy and Pharmacology.
[61] B. Aggarwal,et al. Curcumin‐induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B‐Raf/mitogen‐activated/extracellular signal‐regulated protein kinase pathway and the Akt pathway , 2005, Cancer.
[62] Masaki Kitajima,et al. Antitumor activity of cis‐diamminedichloroplatinum (II) depends on its time × concentration product against human gastric cancer cell lines in vitro , 1995, Journal of surgical oncology.
[63] P. Köpf-Maier,et al. Cytokinetic effects of cisplatin on diverse human head and neck carcinomas in vitro: dependence on the tumor sensitivity to cisplatin , 2005, Journal of Cancer Research and Clinical Oncology.
[64] M. Dobrota,et al. Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine. , 1990, Biochemical pharmacology.
[65] M. Wientjes,et al. Computational model of intracellular pharmacokinetics of paclitaxel. , 2000, The Journal of pharmacology and experimental therapeutics.
[66] I. Ringel,et al. Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. , 1987, The Journal of pharmacology and experimental therapeutics.
[67] G Milano,et al. Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. , 1992, European journal of cancer.
[68] N. Pavlidis,et al. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study , 2002, Anti-cancer drugs.
[69] B. Hill,et al. Concentration and time‐dependent inter‐relationships for antitumour drug cytotoxicities against tumour cells in vitro , 1983, International journal of cancer.
[70] G. Moore,et al. Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma , 1980, International journal of cancer.
[71] T. Secomb,et al. Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. , 2005, Neoplasia.
[72] M. Kornmann,et al. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. , 2000, Anticancer research.
[73] Timothy W Secomb,et al. A mathematical model for cisplatin cellular pharmacodynamics. , 2003, Neoplasia.
[74] P. Parsons. Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. , 1984, Cancer research.